Navigation Links
PLC Announces That Initial Abstract for Presentation of CCM Study of RenalGuard(R) at ESC 2009 Has Been Published; Strong Preliminary Results Seen
Date:8/25/2009

FRANKLIN, Mass., Aug. 25 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that the initial abstract for the investigator-sponsored clinical study of its RenalGuard System(TM) has been published, in advance of the annual meeting of the European Society of Cardiology, August 29 - September 2, 2009 in Barcelona, Spain, on the ESC website.

More comprehensive data are expected to be presented by one of the study's investigators, Dr. Giancarlo Marenzi, Chief, Intensive Cardiac Care Unit, Centro Cardiologico Monzino-University of Milan (CCM) in his session next week during the conference, at which PLC will also be demonstrating RenalGuard((R)).

The abstract details data on 43 patients at high risk for renal failure; the final study will include 120 such patients. The initial results indicate that none of the patients treated with RenalGuard( )while undergoing imaging procedures acquired contrast-induced nephropathy (CIN), but 17% of those who were treated beforehand with overnight hydration did acquire CIN. In fact, two of the patients in that group required temporary renal replacement therapy. Acquiring CIN has been found to lead to a range of serious and potentially deadly outcomes in patients who already have compromised kidney function.

Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "We are extremely pleased with these very positive preliminary results of the CCM clinical trial. These initial results provide encouraging evidence that RenalGuard is highly effective in reducing the incidence of CIN, in millions of high-risk patients around the world every year. While we anticipate that later results may reflect higher rates of CIN with RenalGuard, we are very encouraged by the dramatic benefit already demonstrated by the initial results of the study."

The CCM trial, known as MYTHOS, is a randomized clinical trial designed to provide an assessment of the potential benefits of induced diuresis with automated matched hydration therapy utilizing RenalGuard, compared to standard overnight hydration, a prevalent method of treatment in the EU, in the reducing the incidence of CIN in patients undergoing cardiac catheterization procedures and percutaneous coronary interventions with baseline impairment in renal function. The study is designed as a non-inferiority trial, with the primary endpoint defined as equivalency or better to overnight hydration.

The investigators for the trial are Dr. Antonio L. Bartorelli, Director, Interventional Cardiology, CCM, and Professor of Cardiology, University of Milan, and Dr. Marenzi, two of the world's leading experts on CIN.

PLC received the CE Mark Certificate for the RenalGuard System in December 2007, and concluded its pilot safety trial in the U.S. late in 2007. The company has received full approval from the FDA to commence a U.S. pivotal trial to study the effectiveness of RenalGuard in reducing the incidence of CIN. In March 2008, PLC signed its first international distribution agreement for RenalGuard with Artech s.r.l., Cavezzo, Italy for distribution of its RenalGuard System into Italy, and in May 2009, PLC announced its second European distributor, IZASA Distribuciones Tecnicas S.A., headquartered in Barcelona, Spain, for the distribution of RenalGuard in Spain.

About PLC Systems Inc.

PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. PLC's newest product, RenalGuard, is approved for sale in the EU as a general fluid balancing device. Additional company information can be found at www.plcmed.com.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, we may be unable to raise sufficient funds in the future to implement our business plan and/or commence our planned U.S. clinical trial for RenalGuard, the current clinical trials in Italy and the planned future U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2008, and our other SEC reports.

PLC Systems, PLC Medical Systems, PLC and CO2( )Heart Laser, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc.

    Contact:  Mary T. Conway
    Conway Communications
    617-244-9682
    mtconway@att.net


'/>"/>
SOURCE PLC Systems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Delcath Systems, Inc. Announces Patient Recruitment Exceeds 90%
2. iMedX Announces Acquisition of Worldtech Inc.
3. South Palm Orthospine Institute: World Renowned Spine Specialist and Medical Author, Dr. Stewart G. Eidelson Announces New Additions, Blogs & Twitter !
4. YORK Label Announces Continued Investment in the Company
5. Accuray Announces Results for Fourth Quarter and Fiscal Year 2009
6. Avacor(R), a Leader in Hair Regrowth, Announces Charities of Choice: Team Continuum and City of Hope
7. Prostate Net Announces: Major Medical Education Initiative for Patients, Caregivers and Healthcare Professionals
8. TrinityCare Senior Living Announces Funding Agreement for Senior Living Community Near Knoxville
9. Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office
10. Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
11. Simcere Announces Strategic Partnership with Sun Yat-Sen University Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... Parkinson’s disease (PD) in persons with a specific LRRK2 mutation, according to a ... , Previous studies have provided evidence of a link between pesticides and incidence ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, expert standing desk ... and advantages built into the home office sit stand solution are bold colors, ... to gain the benefits embedded in the TaskMate Go are available 24/7 through ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release of ... in Cannes (France), XO Private has initiated a second print-run of its lavish luxury ... a metre across when open, weighs in at more than six kilos, retails at ...
(Date:2/24/2017)... ... ... An in-depth computational analysis of genetic variants implicated in both schizophrenia and ... may explain why susceptibility to one of the disorders could place individuals at lower ... the journal npj Schizophrenia. , “There is a wealth of genomic data on ...
(Date:2/24/2017)... ... ... Smart Machine Age is here, and it’s disrupting everything. Not only could it drive ... United States may be taken over by technology in the next five to fifteen ... colleagues is drawing to a close. Success will belong to those who can quiet ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Biophysics Corporation, a global medical device manufacturer based in ... growth in 2016 when compared to the previous year based ... fueled by its AffloVest® sales in the United ... global sales of surgical product lines. Said H. ... 25 th year in delivering high-quality, innovative medical devices ...
(Date:2/27/2017)... (NASDAQ: IPXL ) today announced that it plans to participate ... James and Associates, 38 th Annual Institutional Investors Conference at ... Cowen and Company 37 th Annual ... Boston, MA. Barclays Global Healthcare ... FL. Individuals may listen to the ...
(Date:2/27/2017)... Israel , Feb. 27, 2017 ... of adult stem cell technologies for neurodegenerative diseases, announced ... M.D., Ph.D., FACP, and Arturo O. Araya , ... "Dr. Almenoff and Mr. Araya are talented and ... time for our company," said Chaim Lebovits , ...
Breaking Medicine Technology: